Chardan Capital Keeps Their Buy Rating on Editas Medicine (EDIT)

By Jason Carr

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Editas Medicine (EDITResearch Report), with a price target of $55.00. The company’s shares closed last Monday at $30.32, close to its 52-week high of $31.78.

According to TipRanks.com, Livshits is a 5-star analyst with an average return of 21.8% and a 74.4% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Editas Medicine with a $42.50 average price target.

See today’s analyst top recommended stocks >>

Based on Editas Medicine’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $32.94 million. In comparison, last year the company had a GAAP net loss of $15.24 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9).